Ginkgo Bioworks Holdings (DNA) Goodwill & Intangibles (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Goodwill & Intangibles came in at $48.9 million in Q1 2026, down 28.94% YoY from $68.8 million in Q1 2025, and down 8.64% on a QoQ basis from $53.5 million in Q4 2025.
Analysis
Ginkgo Bioworks Holdings (DNA) Goodwill & Intangibles (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 8 years of Goodwill & Intangibles data on file, last reported at $48.9 million in Q1 2026.
- Quarterly Goodwill & Intangibles fell 28.94% year-over-year to $48.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.9 million (down 28.94% YoY) and the FY2025 annual result came in at $53.5 million, down 26.24% from the prior year.
- Goodwill & Intangibles fell to $48.9 million in Q1 2026, from $53.5 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $171.3 million in Q4 2022 to a low of $41.9 million in Q1 2022.
- A 5-year average of $88.1 million and a median of $72.5 million in 2024 frame the typical range for Goodwill & Intangibles.
- Annual changes were most pronounced in 2022 — Goodwill & Intangibles jumped 298.68% — and 2024, when it tumbled 49.71%.
- Tracing DNA's Goodwill & Intangibles over 5 years: stood at $171.3 million in 2022, then dropped by 22.93% to $132.0 million in 2023, then plunged by 45.06% to $72.5 million in 2024, then slipped by 26.24% to $53.5 million in 2025, then decreased by 8.64% to $48.9 million in 2026.
- The last three Goodwill & Intangibles figures came in at $48.9 million (Q1 2026), $53.5 million (Q4 2025), and $61.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 427.52 Mn | 342.98 Mn | 18.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.39 Mn |
| Mar 31, 2026 | 48.86 Mn |
| Dec 31, 2025 | 53.48 Mn |
| Sep 30, 2025 | 61.52 Mn |
| Jun 30, 2025 | 66.15 Mn |
| Mar 31, 2025 | 68.76 Mn |
| Dec 31, 2024 | 72.51 Mn |
| Sep 30, 2024 | 79.57 Mn |
| Jun 30, 2024 | 90.60 Mn |
| Mar 31, 2024 | 125.32 Mn |
| Dec 31, 2023 | 131.98 Mn |
| Sep 30, 2023 | 158.23 Mn |
| Jun 30, 2023 | 107.23 Mn |
| Mar 31, 2023 | 167.46 Mn |
| Dec 31, 2022 | 171.25 Mn |
| Sep 30, 2022 | 58.94 Mn |
| Jun 30, 2022 | 50.18 Mn |
| Mar 31, 2022 | 41.87 Mn |
| Dec 31, 2021 | 42.95 Mn |
| Sep 30, 2021 | 37.75 Mn |